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Abstract
Purpose of Review A significant proportion of patients evaluated for chest pain have ischemia with non-obstructive coronary
artery disease (INOCA). Studies have shown INOCA is associated with increased risk of major adverse cardiac events and
significant burden on the health care system.
Recent Findings While there is scarce scientific evidence on management of INOCA, the CorMicA trial showed that stratified
medical therapy based on the type of INOCA improved patients’ symptoms and quality of life. There are multiple ongoing
trials, including Women’s IschemiA Trial to Reduce Events in Non-ObstRuctIve CORonary Artery Disease (WARRIOR
trial), assessing the benefit of intensive medical therapy versus usual care for this increasingly recognized clinical entity.
Summary In this review, we discuss the definition of INOCA, epidemiology and risk factors, pathophysiology, and management as well as the current knowledge gaps and ongoing clinical trials in this arena.
Keywords Ischemia with non-obstructive coronary arteries · Ischemia · Angina · Microvascular dysfunction · Vasospastic
angina

Introduction
Coronary artery disease (CAD) remains the leading cause of
mortality and morbidity in both men and women in the USA
and worldwide [1]. Classically, CAD has been linked with
obstructive atherosclerotic plaques resulting in flow-limiting
stenotic lesions in one or more epicardial coronary arteries [1, 2]. Recently, there has been growing interest in the
entity of non-obstructive CAD, also known as “open artery
ischemia,” in which a patient presents with symptoms and/
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or signs of myocardial ischemia but the epicardial coronary
artery shows < 50% diameter stenosis [2, 3]. These patients
might have subtle chronic presentation with chronic stable
angina, or non-specific symptoms with objective evidence of
myocardial ischemia. These patients may be classified under
the definition of “ischemia with non-obstructive coronary
arteries (INOCA).” This syndrome is often a direct result of
demand–supply mismatch leading to inadequate myocardial
perfusion secondary to limitations of the microvasculature
[2, 3]. Although previously viewed as “benign,” there is
accumulating evidence indicating that INOCA is associated
with poor quality of life, significant burden on the health
care system, and major adverse cardiac events (MACE),
including acute coronary syndrome, heart failure hospitalization, stroke, and repeat cardiovascular procedures [2–4].
In this review, we discuss the definition of INOCA, epidemiology, risk factors, and management as well as knowledge
gaps and ongoing clinical trials.

Definition of INOCA
The Cardiovascular Disease in Women Committee of the
American College of Cardiology, in conjunction with interested parties (from the National Heart, Lung, and Blood
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Institute, American Heart Association, and European Society of Cardiology), convened a working group to develop
a consensus on the syndrome of myocardial ischemia with
no obstructive coronary arteries (INOCA) [4]. In that scientific statement, INOCA was defined as follows: (1) stable chronic (several weeks or longer) symptoms suggesting
ischemic heart disease such as chest discomfort with both
classic (angina pectoris) and non-classical features in terms
of location, quality, and inciting factors; (2) objective evidence for myocardial ischemia from the electrocardiography
(ECG) or cardiac imaging (echocardiography, nuclear imaging, magnetic resonance imaging, or spectroscopy) at rest
or during stress (exercise, mental, or pharmacological); and
(3) absence of flow-limiting obstruction by coronary angiography (invasive or computed tomographic angiography)
as defined by any epicardial coronary artery diameter reduction ≥ 50% or fractional flow reserve ≤ 0.8 [4].
Similarly, INOCA was defined by a consensus statement
from the European Society of Cardiology Working Group on
Coronary Pathophysiology & Microcirculation, which was
also endorsed by the Coronary Vasomotor Disorders International Study (COVADIS) group, as a demand–supply mismatch of coronary artery blood flow leading to transient or
recurrent cardiac chest pain related to myocardial ischemia
[5•]. The mismatch between blood supply and myocardial
oxygen demand may be caused by coronary microvascular dysfunction (CMD) and/or epicardial coronary artery
spasm, typically in the setting of non-obstructive coronary
atherosclerosis. The working group provided diagnostic criteria for microvascular angina to include the all the following: (1) symptoms of myocardial ischemia, (2) absence of
obstructive CAD (< 50% diameter reduction or FFR > 0.80),
(3) objective evidence of myocardial ischemia whether on
electrocardiography or stress testing, and (4) evidence of
impaired coronary microvascular function [5•] (Table 1).
Although the INOCA definition is generally reserved
for patients who have documented objective ischemia, it is
important to note that we do not have adequate testing to
assure the absence of myocardial ischemia among patients
with coronary microvascular dysfunction [2, 3]. At the present time, cardiac positron emission tomography and magnetic resonance perfusion imaging modalities appear to be

the best options, but they are limited by their spatial resolution. Recent angiographic techniques with computational
fluid dynamic evaluation to assess absolute coronary flow
and coronary microvascular resistance using data from routine invasive coronary angiography may be more accurate;
however, the clinical benefit of these techniques needs to be
evaluated in future studies [6].

Epidemiology and Risk Factors
INOCA is relatively common among patients presenting
with ischemic chest pain [2–4]. Approximately 3 to 4 million women and men with signs/symptoms suggestive of
myocardial ischemia have non-obstructive CAD in the USA
[4]. In an analysis from the National Cardiovascular Data
Registry Cath-PCI Registry of 661,063 patients without history of CAD undergoing elective coronary angiography, the
majority (58.4%) had evidence of non-obstructive CAD [7].
Studies have shown that approximately 60% of women and
30% of men who present with angina have non-obstructive
lesions [8, 9]. Studies have also shown that INOCA patients
tend to be younger, are likely women, and have non-classical
presentation and low risk non-invasive test findings [7–9].
Furthermore, INOCA patients usually have lower prevalence
of the traditional cardiovascular risk factors such as diabetes mellitus compared with patients with obstructive CAD
[2, 3]. However, it is important to note that the presence of
comorbidities, such as diabetes mellitus and hypertension,
has long been linked with CMD which is associated with
some of the detrimental effects observed in both structural
and functional CMD [2, 3].

Pathophysiology
The underlying mechanisms involved in the pathophysiology for INOCA are multifactorial [10–12]. However, CMD
remains a central component in the pathophysiology of
INOCA. CMD may be broadly classified into 2 endotypes:
structural CMD and functional CMD [10]. Structural CMD
is characterized by reduced microvascular conductance and

Table 1  Summary of criteria for diagnosis of INOCA
Criteria

Description

1) Symptoms of myocardial ischemia

Whether it is angina or non-classical symptoms, usually chronic symptoms for
several weeks or longer
< 50% diameter reduction or fractional flow reserve > 0.80
Whether on electrocardiography or cardiac imaging, including echocardiography,
nuclear imaging, magnetic resonance imaging, or spectroscopy
Coronary flow reserve measured invasively or non-invasively, intra-vascular
resistance and acetylcholine response measured invasively

2) Absence of obstructive CAD
3) Objective evidence of myocardial ischemia
4) Evidence of impaired coronary microvascular function
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impaired oxygen delivering capacity to the myocardium. The
decreased microvascular conductance is a result of inward
remodeling of small-sized coronary arterioles, while the
impaired oxygen delivering capacity to the myocardium is a
product of myocardial capillary rarefaction or low coronary
microvascular density [10]. Both inward remodeling of smallsized coronary arterioles and myocardial capillary rarefaction
are commonly seen in structural CMD. Microvascular spasm is
an example of structural CMD, in which dysfunctional vessels
appear to be hypersensitive to acetylcholine and other vasoconstrictors. As with epicardial coronary spasm, microvascular spasm occurs more frequently among women [2, 10, 13].
The co-existence of epicardial spasm makes assessment of the
microcirculation challenging [2, 3].
By contrast, functional CMD represents an impaired flowmediated/endothelium-dependent vasodilation of the microvasculature [10]. Functional CMD is characterized by an
elevated resting flow that is related to enhanced nitric oxide
synthase activity in response to increased myocardial oxygen
demands; thus, a portion of the flow reserve is exhausted,
resulting in the demand–supply mismatch [10]. Similarly,
coronary arterioles’ insensitivity to vasodilatory stimuli and
hypersensitivity to vasoconstrictive stimuli amplify; thus, diffuse stenoses in the microvasculature can result in ischemia.
Vasospastic angina is the clinical manifestation of myocardial ischemia caused by dynamic epicardial coronary
obstruction due to a vasomotor disorder. Epicardial vessel
spasm typically occurs when a hyper-reactive epicardial coronary vessel segment undergoes near-maximal contraction
after exposure to vasoconstrictor stimuli, such as smoking,
cold temperature, drugs, elevation in blood pressure, emotional stress, or hyperventilation. Concomitant vasospastic
angina and CMD is associated with a worse prognosis versus
either condition alone [13].
Heightened inflammation noted by elevation of proinflammatory markers, including C-reactive protein, IL-6,
IL-1, etc., is associated with reduced coronary flow reserve
and CMD [14, 15]. Chronic inflammation, as evidenced by
elevated high-sensitivity C-reactive protein, is associated
with adverse effects of structural and functional CMD and
exacerbates the severity of angina, potentially explaining the
higher prevalence of INOCA and CMD in women [14, 15].
Furthermore, autonomic nervous system activation, whether
cardiac or central, is associated with intensification of the
detrimental effects of functional CMD by impairing modulation between vasodilatory and vasoconstrictive stimuli [2, 3]

Diagnosis of INOCA
INOCA remains potentially underdiagnosed and thus undertreated. The diagnosis of INOCA is key to provide optimal care for these patients (Fig. 1). Briefly, these patients

usually present with symptoms and/or signs of myocardial
ischemia, alongside objective evidence of ischemia, whether
on electrocardiogram or one of the various cardiac imaging modalities (echocardiography, nuclear imaging, magnetic resonance imaging, or spectroscopy), and absence
of obstructive coronary arteries on an invasive coronary
angiogram or computed tomography (stenosis of < 50%,
FFR > 0.8) [1–4]. Further invasive diagnostic testing might
be needed, including coronary artery functional testing (e.g.,
invasive coronary flow reserve, intravascular resistance, and
acetylcholine response) to confirm the type of INOCA [2–4,
5•].

Management of INOCA
It is important to emphasize that management of INOCA
should be patient-centered based on the subtype and comorbidities, with a multidisciplinary care approach focusing
on lifestyle modification and aggressive risk factor control,
including blood pressure, glycemic and lipid management,
along with smoking cessation and exercise/activity promotion [5•] (Fig. 2). Treatment of underlying comorbidities and
avoiding known triggering factors are also key [5•].
Studies have suggested that certain medications maybe
associated with benefit in this heterogenous group of
patients. Numerous medications have been studied, including conventional cardiac medications (e.g., nitrates, betablockers, angiotensin converting enzyme inhibitors (ACEIs)/
angiotensin receptor blockers (ARBs), and ranolazine,
among others) as well as non-conventional treatment (for
example, hormonal replacement therapy, exercise, tricyclic
anti-depressants, and spinal cord stimulation, among other
modalities) [16–19]. Beta-blockers, ACEIs, and statins have
shown some promise in CMD [1–3, 16–24]. However, most
data on both conventional and non-conventional therapies
are driven from observational studies [2–4, 5•, 16–22]. One
of the few randomized trials in this field is CorMicA, which
included patients with symptoms of myocardial ischemia
undergoing invasive coronary angiography [20]. Among the
151 patients with non-obstructive CAD, stratified medical
therapy based on the type of CMD led to improvement in
symptoms and outcomes [20]. Using this strategy, physicians were more likely to prescribe anti-anginal medications
in the intervention group. Similarly, these patients were
more likely to receive calcium channel blockers at 6 months.
The CorMicA trial results, although of small sample size,
showed that stratified therapy based on the type of microvascular dysfunction led to improvement in angina and quality
of life. Patients with coronary vasospasm showed benefit
from vasodilator therapy with calcium channel blockers and/
or nitrate therapy, while patients with microvascular angina
experienced improvement in symptoms with beta-blockers
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Fig. 1  Diagnostic algorithm for patients with INOCA

Fig. 2  Summary of the treatment for INOCA. Abbreviations: INOCA, ischemia with
non-obstructive coronary
arteries; ACEI, angiotensin converting enzyme inhibitor; CCB,
calcium channel blocker

and consideration of ACEI (or equivalent)/statin therapy
[20].
The ACEI therapy has been shown beneficial in CMD by
either directly affecting coronary vascular function through
modulation of the renin–angiotensin–aldosterone pathway,
which also may provide improved blood pressure control.
ACEIs have been associated with improved coronary flow
reserve and coronary flow measurements by increasing
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endothelial nitric oxide bioavailability [17, 21]. The benefit of statins not only comes from its cholesterol-lowering
effect, but also from its anti-inflammatory properties resulting in reduction of oxidative stress [21, 22]. Statins reduce
plaque lipid-rich core, macrophage, and foam cell formation,
decrease platelet reactivity, and promote fibrous cap thickening, leading to reduction in downstream microembolization
and thrombotic events [21].
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More recently, the IMPROvE-CED phase 1/2 trial
showed proof of concept using intra-coronary autologous
CD34 + cell therapy for CMD [23, 25]. The study included
20 patients; 75% were women. There was a significant
improvement in angina scores and coronary blood flow
at 6 months compared with a standard of care group who
received maximally tolerated medical therapy alone [23,
25].
These findings led to the Women’s IschemiA Trial to
Reduce Events in Non-ObstRuctIve CORonary Artery
Disease (WARRIOR trial, NCT03417388). This is a multicenter, prospective, randomized, open, blinded outcomes
evaluation (PROBE design) pragmatic trial investigating the
efficacy of an intensive medical treatment (IMT) strategy
versus usual care (UC) for prevention of cardiovascular disease (MACE) events (primary outcome) in 4,422 women
with symptoms and/or signs of IHD without obstructive
CAD (e.g., INOCA). Additionally, quality of life and treatment satisfaction (SAQ) will also be evaluated among several secondary outcomes [24, 26•]. To further understand
the biology of statin, RAS blocker, and aspirin effects
used in the IMT strategy, 900 women are co-enrolled in an
embedded mechanistic substudy that will determine effects
of potent statins and ACEIs or ARBs on non-calcified plaque
volume and high-risk plaque morphology using coronary
computed tomographic angiography, as well as on blood
biomarkers of vascular inflammation and immune activation.
The Precision Medicine With Zibotentan in Microvascular Angina (PRIZE) (NCT04097314) is a trial assessing
benefit of zibotentan, an oral endothelin A receptor antagonist, in patients with microvascular dysfunction [27]. The
hypothesis behind the use of this medication in INOCA is
that the minor G allele of the non-coding single nucleotide
polymorphism enhances expression of the endothelin-1 gene
in human vascular cells, increasing circulating concentrations of endothelin, and the prevalence of this allele is higher
in patients with ischemic heart disease [27]. The primary
outcome of the PRIZE trial is to assess the treadmill exercise
duration [27].

The CorCTCA (NCT03477890) is another ongoing trial
aiming to clarify the prevalence and outcomes of INOCA
when coronary computed tomography angiography is used
as the initial diagnostic modality [28]. The primary outcome
is reclassification of the initial computed tomography’s diagnosis based on the interventional diagnostic procedure [28].
As biomarkers to detect ischemic myocardial injury
continue to improve, myocardial infarction (MI) with open
coronary arteries is increasingly observed and may contribute to 10–15% of the MI population. The Randomized
Evaluation of Beta Blocker and ACEI/ARB Treatment in
MINOCA Patients—MINOCA-BAT (NCT 03,686,696) is
underway in Europe, Australia, and the USA. The primary
objective of this pragmatic, randomized trial is to determine
whether oral beta-blockade compared to no oral beta-blockade, and whether management with ACEI/ARB, compared
with no ACEI/ARB, reduces all-cause death and readmission because of acute MI, ischemic stroke, or heart failure
in patients discharged with MINOCA and with no clinical
signs of heart failure and with LVEF ≥ 40%.
The few ongoing trials in this arena to address the optimal therapy in these patients with INOCA are summarized
in Table 2.

Knowledge Gaps and Ongoing Trials
There is a paucity of strong evidence evaluating the optimal
therapy in patients with signs and/or symptoms of suspected
ischemia and non-obstructive CAD, as our current data are
mainly based on observational studies with the exception of
CorMicA trial [20]. While CorMicA showed evidence supporting the benefit of an algorithmic approach to patients
with suspected CMD with stratified treatment based on the
specific endotype of CMD, CMD remains a heterogenous
clinical condition with knowledge gaps in understanding the
pathophysiology with potential disease mechanisms, interactions of different risk factors, cost-effective diagnostic testing, and optimal management options with their impact on

Table 2  Summary of ongoing trials in syndrome of ischemia with non-obstructive coronary arteries (INOCA)
Trial

Objective

The WARRIOR trial (NCT03417388) [24, 26•]

Evaluate the benefit of intensive medical therapy with statin, angiotensin-converting enzyme
inhibitors/angiotensin receptor blocker therapy, aspirin and lifestyle counseling and their
impact on major adverse cardiac events in symptomatic women with INOCA
The Precision Medicine With Zibotentan in Microvascular Angina (PRIZE) trial’s goal is to
assess the benefit of zibotentan, an oral endothelin A receptor antagonist, in patients with
microvascular dysfunction. The primary outcome of the PRIZE trial is to assess the treadmill exercise duration using the Bruce protocol
The trial’s aim is to clarify the prevalence and outcomes of INOCA when coronary computed
tomography angiography is used as the initial diagnostic modality. Primary outcome is
reclassification of the initial computed tomography’s diagnosis based on the interventional
diagnostic procedure

The PRIZE trial (NCT04097314) [27]

The CorCTCA trial (NCT03477890) [28]
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outcomes as well as prognosis of different types of CMD.
Moreover, INOCA may be associated with higher risk of
developing heart failure with preserved ejection fraction,
through potential mechanisms including ventricular remodeling and aortic stiffness. However, this association is not
completely understood, and future studies addressing this
knowledge gap are needed [29, 30].
Observational studies have shown potential benefit of
ACEIs and statins, as well as beta-blockers; however, the
benefit of these medications compared with no medication
has not been confirmed in large randomized clinical trials
[16–20]. Thus, large randomized clinical trials are needed to
confirm the benefit and role of the different pharmacological
and behavioral treatments.

2.

3.

4.

5.

Conclusions
INOCA is increasingly recognized as a heterogenous clinical
entity, mainly affecting women. Diagnosis of INOCA is key,
because recognizing which INOCA endotype the patient has
guides our management, as illustrated by the CorMicA trial.
There is still scarcity of evidence in the optimal therapy for
these patients. However, there are current, ongoing clinical
trials enrolling patients, and these trials will help us answer
some of these questions in INOCA and CMD.
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